# US 2021/0077993 A1 · Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0077993 A1
- Document ID: US20210077993A1
- Status: Published application
- Kind: A1
- Application number: 17/050,243
- Filed: 2019-04-25
- Published: 2021-03-18
- Earliest claimed: 2018-04-25
- Assignees: BG Research Ltd
- Applicants: Bg Research Ltd
- Inventors: Nelson Nazareth; David Edge; Adam Tyler; Matthew Sadler
- Web page: https://patentgrep.com/patent/US20210077993A1

## CPC

- B01L 3/508: {Rigid containers without fluid transport within}
- B01L 3/5021: {Test tubes specially adapted for centrifugation purposes}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/686: Polymerase chain reaction [PCR]
- B01L 7/52: {with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples}
- B01L 2200/0689: Sealing
- B01L 2200/10: Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
- B01L 2200/141: Preventing contamination, tampering
- B01L 2300/021: Identification, e.g. bar codes
- B01L 2300/042: Caps; Plugs
- B01L 2300/0832: cylindrical, tube shaped
- B01L 2300/12: Specific details about materials
- B01L 2400/0409: centrifugal forces
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to bio-secure means for the detection of pathogens and provides a bio-secure reaction vessel and methods of preparing a sample for PCR-based pathogen detection. The reaction vessel comprises a reaction chamber portion (1); a cap holder portion (2); and a cap (3). Two points of security, such as two O-ring seals (9, 10), are provided between the cap (3) and the reaction chamber portion (1). A first seal (9) may be located at a top of the cap holder portion (2) and a second seal (10) may be located at a base of the cap (10).

## Claims

### Claim 1

A vessel comprising:
a reaction chamber portion;
a cap holder portion having a means for attaching a cap in such a way that when the cap is engaged with the vessel there are at least two points of security between the cap and the reaction chamber portion;
and a cap.

### Claim 2 (depends on 1)

The vessel of claim 1 wherein the vessel is a disposable vessel.

### Claim 3 (depends on 1, 2)

The vessel according to any of claim 1 or 2 wherein the vessel is suitable for field use.

### Claim 4 (depends on 1, 2, 3)

The vessel according to any of claims 1-3 wherein the vessel is a bio-secure vessel.

### Claim 5 (depends on 1, 2, 3, 4)

The vessel according to any of claims 1-4 wherein the vessel is suitable for use in a PCR reaction, optionally suitable for use in real-time PCR.

### Claim 6 (depends on 5)

The vessel according to claim 5 wherein the PCR is for the identification of pathogens,
optionally pathogens selected from:
a) the group consisting of viruses, bacteria, fungi, parasites; and/or
b) Class 4 or 3 pathogens; and/or pathogens that cause the diseases selected from the group consisting of:
c) Malaria, HIV, viral hepatitis, soil transmitted helminth parasitic infections;
d) Viral haemorrhagic fevers selected from the group consisting of Ebola, Lassa fever, Marburg virus disease, Rift valley fever, Congo fever; and/or
e) Japanese encephalitis, Dengue, Zika, Chikungunya, yellow fever.
f) Veterinary diseases with a viraemic component, including but not limited to PPRV, FMDV, BTV, Newcastle disease, Swine Flu, BVDV.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The vessel according to any of claims 1-6 wherein the reaction chamber is formed of a carbon loaded polymer, optionally is formed from a polymer that can withstand temperatures of up to 110° C., optionally formed from polypropylene.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The vessel according to any of claims 1-7 wherein the vessel comprises a window, optionally a translucent window, optionally wherein the translucent window is suitable for the excitation of and/or detection of emissions from, fluorophores located within the vessel.

### Claim 9 (depends on 8)

The vessel according to claim 8 wherein the window is located within the cap portion of the vessel.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The reaction vessel according to any of claims 1-9 wherein at least one of the points of security comprises a seal between the cap and the vessel.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The reaction vessel according to any of claims 1-9 wherein at least two of the points of security comprises a seal between the cap and the vessel.

### Claim 12 (depends on 10, 11)

The reaction vessel according to any of claim 10 or 11 wherein at least one of the seals is located at the top of the cap holder portion.

### Claim 13 (depends on 10, 11, 12)

The reaction vessel according to any of claims 10-12 wherein at least one of the seals is located at the at the base of the cap.

### Claim 14 (depends on 10, 11, 12, 13)

The reaction vessel according to any of claims 10-13 wherein the vessel comprises at least two seals between the cap and the vessel and wherein one of the seals is located at the top of the cap holder portion and wherein one of the seals is located at the base of the cap.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The reaction vessel according to any of claims 10-14 wherein one or both of the at least two seals comprise:
a) an interference fit; and/or
b) a gasket, optionally O-ring seals.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The reaction vessel according to any of claims 1-15 wherein the vessel comprises a locking means designed to prevent easy or accidental separating of the cap from the reaction chamber portion.

### Claim 17 (depends on 16)

The reaction vessel according to claim 16 wherein the locking means comprises a cooperating ramp and a step.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The reaction vessel according to any of claims 1-17 wherein the cap holder portion and the reaction chamber portion are a single entity, optionally wherein the cap holder portion is formed to the reaction chamber portion.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The reaction vessel according to any of claims 1-18 wherein the cap holder portion is formed of polypropylene.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The reaction vessel according to any of claims 1-19 wherein the cap holder portion and the cap comprise a complementary screw thread enabling the attachment of the cap to the cap holder portion.

### Claim 21 (depends on 20)

The reaction vessel according to claim 20 wherein the cap requires less than 5, optionally less than 4, 3, 2, or 1 turn on the screw thread to securely attach the cap to the cap holder portion.

### Claim 22 (depends on 20, 21)

The reaction vessel according to any of claim 20 or 21 wherein the vessel comprises a stop arranged to prevent overtightening of the cap.

### Claim 23 (depends on 20, 21, 22)

The reaction vessel according to any of claims 20-22 wherein the vessel comprises a wing on the cap holder portion for attaching a label to or for inscribing thereon, optionally for attaching an identifier label or inscribing an identifier.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The vessel according to any of claims 1-26 wherein the vessel is suitable for being held in a centrifuge.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The vessel according to any of claims 1-24 wherein the vessel is constructed to enable heating of the cap.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The vessel according to any of claims 1-25 wherein the reaction chamber is of microtitre capacity, optionally has a capacity of less than 1000 ul, optionally less than 900 ul, 800 ul, 700 ul, 600 ul, 500 ul, 400 ul, 300 ul, 250 ul, 200 ul, 150 ul, 100 ul, 50 ul or less than 20 ul. the vessel is about 200 ul volume

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The reaction vessel according to any of claims 1-26 wherein the reaction chamber portion is formed of a carbon loaded polymer and wherein the carbon loading is at least 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70% by weight.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The vessel according to any of claims 1-27 wherein the reaction chamber is formed of polyurethane, optionally formed of polyurethane loaded with at least 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70% carbon by weight.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The reaction vessel according to any of claims 1-28 wherein the vessel is between 3-5 cm in length and where the vessel comprises a wing or wings, is between around 3-4 cm in breadth.

### Claim 30

A method for preparing a sample for reverse transcription (RT), PCR, or RT-PCR, optionally for qPCR, optionally for RT qPCR, wherein the method comprises centrifuging the sample within a closed vessel and wherein the vessel is the same vessel as the PCR is to subsequently be performed in.

### Claim 31 (depends on 30)

The method of claim 30 wherein no part of the sample is removed from the vessel:
a) prior to PCR being performed; and/or
b) following PCR being performed
optionally wherein once the sample is added to the vessel, no material is removed from the vessel:
a) prior to PCT; and/or
b) during PCR; and/or
c) following PCR.

### Claim 32 (depends on 30, 31)

The method of any of claim 30 or 31 wherein the sample is a crude sample.

### Claim 33 (depends on 30, 31, 32)

The method of any of claims 30 to 32 wherein the sample is a crude biological sample or a crude environmental sample.

### Claim 34 (depends on 30, 31, 32, 33)

The method of any of claims 30-33 wherein the sample is:
a) a swab; and/or
b) eluate taken from a wash of a swab.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The method of any of claims 30-34 wherein the sample is a sample that may comprise one or more pathogens, optionally may comprise pathogens selected from:
a) the group consisting of viruses, bacteria, fungi; and/or
b) class 4 or 3 pathogens; and/or
pathogens that cause the diseases selected from the group consisting of:
c) Viral haemorrhagic fevers selected from the group consisting of Ebola, Lassa fever, Marburg virus disease, Rift valley fever, Congo fever and yellow fever; and/or
d) Japanese encephalitis, Dengue, Zika, Chikungunya.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The method of any of claims 30-35 wherein the sample comprises particulate or cellular matter.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35, 36)

The method of any of claims 30-36 wherein the sample comprises a substance, or releases a substance, that is inhibitory to PCR, optionally releases a substance upon heating that is inhibitory to PCR.

### Claim 38 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The method of any of claims 30-37 wherein the sample is selected from the group comprising blood, faeces, urine, plasma, serum, CSF, eluate from swabs taken from a subject, optionally taken from the eyes, ears, nose or mouth.

### Claim 39 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The method of any of claims 30-37 wherein the centrifugation is performed at a speed and for a duration so as to result in pelleting a first fraction of the sample whilst leaving a second fraction of the sample in the supernatant.

### Claim 40 (depends on 39)

The method of claim 39 wherein where the sample is blood the first fraction comprises red blood cells and the second fraction comprises white blood cells and any viruses or bacteria present in the sample.

### Claim 41 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any of claims 30-40 wherein the centrifugation is performed at less than 1000 g, optionally between 200 g and 1000 g, between 300 g and 900 g, between 400 g and 800 g, between 500 g and 700 g, optionally 600 g; and wherein the centrifugation is performed for less than 60 seconds, optionally between 5 and 60 seconds, optionally between 10 and 55, 15 and 50, 20 and 45, 25 and 40, 30 and 35 seconds;
optionally wherein the centrifugation is performed at 500 g for 30 seconds.

### Claim 42 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any of claims 30-41 wherein the vessel comprises PCR reaction components, optionally comprises any one or more of a polymerase and or PCR primers, optionally wherein the reagents are lyophilised.

### Claim 43 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any of claims 30-42 wherein the centrifugation takes place prior to commencement of RT and PCR.

### Claim 44 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any of claims 30-41 wherein the centrifugation takes place during RT and/or PCR, optionally wherein the centrifugation takes place
a) after the RT step (if present) but prior to PCR; or
b) after RT and after between 1-5 cycles of PCR

### Claim 45 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any of claims 30-44 wherein the centrifugation takes place prior to commencement of PCR and during PCR.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 39, 40, 41, 42, 43, 44, 45)

The method of any of claims 39-45 wherein the method is performed in a vessel as defined in any of claims 1-29.

### Claim 47 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A method of performing RT, PCR, or RT-PCR wherein the sample is prepared according to any of claims 30-46.

### Claim 48 (depends on 47)

The method according to claim 47 where the PCR is qPCR or the RT-PCR is RT-qPCR, optionally wherein the excitation wavelength used to excite the fluorophore associated with the qPCR is between 630 nm-645 nm, optionally between 633 nm-642 nm;
and/or the emitted light is collected at a wavelength of between 650 nm-750 nm.

### Claim 49 (depends on 47, 48)

The method according to any of claims 47 and 48 wherein the fluorophore is excited at a wavelength of around 475 nm and/or 635 nm; and/or the emitted light is collected at a wavelength of around 520-50 nm and 660-750 nm.

### Claim 50 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A closed-tube method of performing PCR wherein the sample is prepared according to any of claims 30-46, optionally wherein the presence of the PCR product is detected without removing any material from the vessel.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 50)

The method according to claim 50 wherein the vessel is a vessel as defined in any of claims 1-29.

### Claim 52 (depends on 47, 48, 49, 50, 51)

The method according to any of claims 47-51 wherein the sample comprises at least 5% of the PCR reaction volume, optionally at least 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% or 35% or greater; optionally comprises 13% of the reaction volume.

### Claim 53 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A method for the detection of a pathogen wherein the method comprises the method of any of claims 30-52.

### Claim 54 (depends on 53)

The method according to claim 53 wherein the method comprises detection of the presence of the amplification product.

### Claim 55 (depends on 54)

The method of claim 54 wherein detection of the amplification product indicates presence of the pathogen.

### Claim 56 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A method for diagnosing a subject as being infected with a target pathogen, wherein the method comprises the method according to any of claims 30-55.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A vessel according to any of claims 1-29 wherein the vessel comprises PCR reaction components, optionally comprises one or more of a polymerase or PCR primers, optionally wherein the reaction components are lyophilised.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 53)

A kit comprising a vessel according to any of claim 1-29 or 53 and any one or more of:
PCR primers;
Polymerase;
a resuspension buffer;
positive and/or negative control samples;
pipettes.
